NCT06859099

Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

ENROLLING_BY_INVITATIONPHASE3INTERVENTIONAL

Trial Details

Start: 2025-04-01Est. Completion: 2029-10-03

Enrollment target: 300 participants

Locations

Alabama Neurology Associates- Site Number : 8400019, Homewood, Alabama, United States
Honor Health Scottsdale Osborn Medical Center- Site Number : 8400014, Scottsdale, Arizona, United States
University of Kansas Medical Center- Site Number : 8400010, Kansas City, Kansas, United States
Columbia University Irving Medical Center- Site Number : 8400003, New York, New York, United States
Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022, Philadelphia, Pennsylvania, United States
Investigational Site Number : 0320003, Buenos Aires, Argentina
L2IP - Instituto de Pesquisas Clínicas- Site Number : 0760006, Brasília, Federal District, Brazil
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760004, Ribeirão Preto, São Paulo, Brazil
PSEG Centro de Pesquisa Clínica- Site Number : 0760009, São Paulo, Brazil
Investigational Site Number : 1000002, Blagoevgrad, Bulgaria
Investigational Site Number : 1240001, Gatineau, Quebec, Canada
Investigational Site Number : 1240002, Québec, Quebec, Canada
Investigational Site Number : 1520003, Lo Barnechea, Reg Metropolitana de Santiago, Chile

B-cell Mediated Autoimmune Disorders

The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-c…

La Jolla, United StatesEst. completion Dec 1, 2026

Chronic Inflammatory Demyelinating PolyneuropathyCIDPChronic Inflammatory Demyelinating Polyradiculoneuropathy

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study…

Birmingham, United StatesEst. completion Oct 7, 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.